Literature DB >> 18510526

Diagnosis of factor VIII deficiency.

B Verbruggen1, P Meijer, I Novákova, W Van Heerde.   

Abstract

The correct diagnosis of factor VIII deficiency and the assessment of severity of the disease are essential for a patient-tailored treatment strategy. An optimal diagnostic procedure comprises sensitive and specific screening methods and factor VIII activity assays. Different screening reagents show variable characteristics and receiver operator characteristic curves are presented showing the relation between sensitivity and specificity of eleven activated partial thromboplastin time reagents. The details of the three methods for factor VIII activity assay, one-stage and two-stage assay and chromogenic assays, are discussed. The chromogenic assay seems to be more sensitive than the one-stage assay with regard to the detection of severe haemophilia. Discrepant results obtained with one-stage and two-stage assays are reviewed and discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18510526     DOI: 10.1111/j.1365-2516.2008.01715.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  9 in total

Review 1.  Perils, problems, and progress in laboratory diagnosis of von Willebrand disease.

Authors:  Veronica H Flood
Journal:  Semin Thromb Hemost       Date:  2013-12-12       Impact factor: 4.180

2.  Challenges in the Diagnosis and Management of Non-Severe Hemophilia.

Authors:  Estera Boeriu; Teodora Smaranda Arghirescu; Margit Serban; Jenel Marian Patrascu; Eugen Boia; Cristian Jinca; Wolfgang Schramm; Adina Traila; Cristina Emilia Ursu
Journal:  J Clin Med       Date:  2022-06-09       Impact factor: 4.964

3.  Specific and global coagulation tests in patients with mild haemophilia A with a double mutation (Glu113Asp, Arg593Cys).

Authors:  Alenka Trampuš Bakija; Maruša Debeljak; Irena Preložnik Zupan; Majda Benedik Dolničar; Jernej Kovač; Janez Jazbec
Journal:  Blood Transfus       Date:  2015-05-15       Impact factor: 3.443

4.  Method validation and clinical utility of chromogenic factor VIII assay compared to one-stage assay.

Authors:  Wilmare Gouws; Elsabie Botha; Adele Visser
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

5.  Coagulation assessment with thromboelastography during abdominal endovascular aneurysm repair in a patient with hemophilia A.

Authors:  Kazuki Sato; Nobuyuki Katori; Yoshifumi Suga; Shuya Kiyama; Shoichi Uezono
Journal:  JA Clin Rep       Date:  2020-02-04

6.  From Hemophilia to Deep Venous Thrombosis Patient Samples: How to Perform an Easy Coagulometer Validation Process According to Available Guidelines.

Authors:  Silmara Aparecida de Lima Montalvão; Ana Paula Francisco; Bittar Letícia Queiroz da Silva; Stephany Cares Huber; Helder José Aguiari; Maria Carmem Gonçalves Lopes Fernandes; Priscila Soares Elidio; Beatriz de Moraes Martinelli; Isa Macedo Tony; Marina Pereira Colella; Joyce Maria Annichinno-Bizzachi
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

Review 7.  Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice.

Authors:  Tine M H J Goedhart; Laura H Bukkems; C Michel Zwaan; Ron A A Mathôt; Marjon H Cnossen
Journal:  Blood Adv       Date:  2021-10-26

8.  Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories.

Authors:  J M Sommer; N Moore; B McGuffie-Valentine; S Bardan; Y Buyue; G D Kamphaus; B A Konkle; G F Pierce
Journal:  Haemophilia       Date:  2013-11-22       Impact factor: 4.287

9.  Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme.

Authors:  Iris van Moort; Piet Meijer; Debby Priem-Visser; Adriaan J van Gammeren; Nathalie C V Péquériaux; Frank W G Leebeek; Marjon H Cnossen; Moniek P M de Maat
Journal:  Haemophilia       Date:  2018-11-29       Impact factor: 4.287

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.